OSE Immunotherapeutics (France)

OSE Immunotherapeutics (France)

Open Access statistics for OSE Immunotherapeutics (France), France, covering academic research published from 2000 to 2023.

Open Access statistics for OSE Immunotherapeutics (France), France, covering academic research published from 2000 to 2023. Read More.


Open Access Percentage

64%


Total
Publications

118


Total Open
Publications

76


Total
Citations

2.3K


Open Access
Percentage

64%


Total
Publications

118


Total Open
Publications

76


Total
Citations

2.3K

Website

download

Breakdown

24% 36% 5% 35%

Publisher Open

24%

Both

36%

Other Platform Open

5%

Closed

35%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

02468101214161820Total Publications
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Open

Closed

Publisher Open

41%OA Journal

OA Journal 41%

29

Hybrid 26%

18

No Guarantees 33%

23

Other Platform Open

Domain 75%

36

Institution 54%

26

Other Internet 35%

17

Public 10%

5

Preprint 8%

4

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
36
Europe PMC
Domain
19
Le Centre pour la Communication Scientifique Directe - HAL - Université Paris Descartes
Institution
11
CCSD (Centre pour la Communication Scientifique Directe) - HAL - Nantes Université
Other Internet
11
Le Centre pour la Communication Scientifique Directe - HAL - Diderot
Institution
10
Le Centre pour la Communication Scientifique Directe - HAL - Inserm
Institution
7
Le Centre pour la Communication Scientifique Directe - HAL - Inria
Institution
7
Le Centre pour la Communication Scientifique Directe - HAL - Université de Nantes
Institution
6
Le Centre pour la Communication Scientifique Directe - HAL - TYPE ART
Other Internet
6
Semantic Scholar
Public
5
1 / 3

Data updated 7 October 2024

Share

Share

Share